Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Open Label, Dose-finding run-in and Cohort Expansion Study to Evaluate the Safety, Tolerability and Effectiveness of Tinodasertib in Combination With Pembrolizumab or Irinotecan in Metastatic Colorectal Cancer

NCT05462236 is registered in ClinicalTrials.gov with AUM Biosciences Pte Ltd as lead sponsor.

NCT NCT05462236
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05462236 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Open Label, Dose-finding run-in and Cohort Expansion Study to Evaluate the Safety, Tolerability and Effectiveness of Tinodasertib in Combination With Pembrolizumab or Irinotecan in Metastatic Colorectal Cancer
Lead sponsor
AUM Biosciences Pte Ltd
Phase
Phase 2
Overall status
Recruiting
Start date
April 14, 2023
Completion date
October 15, 2026
Enrollment
120 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer